89bio, Inc. (ETNB) Shareholders to Receive Up to $3.5B Total in Roche Buyout Deal

Core Insights - 89bio, Inc. is recognized as one of the best performing healthcare stocks, focusing on therapies for liver and cardiometabolic diseases, particularly MASH [1] - Roche has agreed to acquire 89bio, Inc. for $14.50 per share, valuing the company at approximately $2.4 billion, with potential additional value based on the success of its lead candidate, pegozafermin [2] - The total deal value could reach around $3.5 billion, reflecting confidence in pegozafermin as a leading therapy for MASH [2][3] Company Overview - 89bio, Inc. is a clinical-stage biopharmaceutical company developing therapies for liver diseases, with a focus on metabolic dysfunction-associated steatohepatitis (MASH) [1] - The lead candidate, pegozafermin, is a long-acting FGF21 analog aimed at treating moderate to severe MASH and related metabolic disorders [1] Acquisition Details - Roche's acquisition plan includes integrating pegozafermin into its cardiovascular, renal, and metabolic portfolio, aiming to leverage its global capabilities for development and commercialization [3] - The transaction is expected to close in Q4 2025, following unanimous board approval from both companies [3]